Delineating the Ligand-Receptor Interactions That Lead to Biased Signaling at the μ-Opioid Receptor

Biased agonists, which selectively stimulate certain signaling pathways controlled by a G protein-coupled receptor (GPCR), hold great promise as drugs that maximize efficacy while minimizing dangerous side effects. Biased agonists of the mu-opioid receptor (mu OR) are of particular interest as a means to achieve analgesia through G protein signaling without dose-limiting side effects such as respiratory depression and constipation. Rational structure-based design of biased agonists remains highly challenging, however, because the ligand-mediated interactions that are key to activation of each signaling pathway remain unclear. We identify several compounds for which the R- and S-enantiomers have distinct bias profiles at the FOR. These compounds serve as excellent comparative tools to study bias because the identical physicochemical properties of enantiomer pairs ensure that differences in bias profiles are due to differences in interactions with the mu OR binding pocket. Atomic-level simulations of compounds at mu OR indicate that R- and S-enantiomers adopt different poses that form distinct interactions with the binding pocket. A handful of specific interactions with highly conserved binding pocket residues appear to be responsible for substantial differences in arrestin recruitment between enantiomers. Our results offer guidance for rational design of biased agonists at mu OR and possibly at related GPCRs.

Automated summary

Biased agonists selectively stimulate certain signaling pathways controlled by GPCRs to maximize efficacy and minimize side effects. Designing biased agonists for the mu OR remains challenging due to unclear ligand-mediated interactions and differences in interaction with the binding pocket may lead to distinct bias profiles.